The development of PSMA-targeted radiopharmaceuticals, including small-molecule anti-cancer drug conjugates, peptides, modified antibodies, radiotherapy, and immunotherapy, holds promise for novel therapeutic approaches in prostate cancer [37,41,42,43]. Here, FOLH1 is linked to prostate cancer.